101968-85-8

Basic information

• Product Name: N-[[(1,1-DiMethylethyl)aMino]carbonyl]-3-Methyl-L-valine
• Synonyms: (2S)-2-(tert-ButylaMinocarbonylaMino)-3,3-diMethylbutanoic Acid;N-[[(1,1-DiMethylethyl)aMino]carbonyl]-3-Methyl-L-valine;N-tert-ButylcarbaMoyl-L-tert-leucine;(S)-2-(3-tert-butylureido)-3,3-diMethylbutanoic acid [;(2S)-2-(tert-butylcarbaMoylaMino)-3,3-diMethyl-butanoic acid;L-Valine,N-[[(1,1-diMethylethyl)aMino]carbonyl]-3-Methyl-;Boceprevir INT 2
• CAS NO: 101968-85-8
• Molecular Formula: C₁₁H₂₂N₂O₃
• Molecular Weight: 230.30398
• EINECS: 1312995-182-4
• Mol File: 101968-85-8.mol
• Article Data: 6

Chemical Properties

• Melting Point: 182 °C(dec.)
• Boiling Point: 407.6°C at 760 mmHg
• Flash Point: 200.3°C
• Appearance: /
• Density: 1.047
• Vapor Pressure: 8.74E-08mmHg at 25°C
• Refractive Index: 1.472
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: Methanol
• PKA: 4.28±0.10(Predicted)
• CAS DataBase Reference: N-[[(1,1-DiMethylethyl)aMino]carbonyl]-3-Methyl-L-valine(CAS DataBase Reference)
• NIST Chemistry Reference: N-[[(1,1-DiMethylethyl)aMino]carbonyl]-3-Methyl-L-valine(101968-85-8)
• EPA Substance Registry System: N-[[(1,1-DiMethylethyl)aMino]carbonyl]-3-Methyl-L-valine(101968-85-8)

Safety Data

• Hazardous Substances Data: 101968-85-8(Hazardous Substances Data)

Usage

Chemical Properties

White Solid

Uses

Reagent in the preparation of therapeutic agents.

InChI:InChI=1/C11H22N2O3/c1-10(2,3)7(8(14)15)12-9(16)13-11(4,5)6/h7H,1-6H3,(H,14,15)(H2,12,13,16)/t7-/m1/s1

Upstream product

• 1609-86-5 Tert-butyl isocyanate 
• 20859-02-3 L-tert-Leucine 
• 75-64-9 tert-butylamine 
• 530-62-1 1,1'-carbonyldiimidazole 
• 10017-37-5 tert-butylamine hydrochloride 

Downstream Products

• 816444-90-3 (1R,2S,5S)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxylic acid 
• 394735-28-5 (1R,2S,5S)-N-(4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-(tert-butyl)ureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicylo[3.1.0]-hexane-2-carboxamide 
• 394730-60-0 boceprevir 
• 394735-27-4 methyl (1R,2S,5S)-3-((S)-2-(3-(tert-butyl)-ureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxylate 

Relevant articles and documents

Synthesis and Process Optimization of Boceprevir: A Protease Inhibitor Drug

Efforts toward the synthesis and process optimization of boceprevir 1 are described. Boceprevir synthesis was optimized by telescoping the first three steps and last two steps of the five-step process. Optimization of oxidation, which is one of the critical steps in the total synthesis, is discussed. A control strategy for the three impurities is described. A novel process for the synthesis of fragment A (2) has been developed, which is the key starting material for the synthesis of boceprevir.

PROCESS FOR PRODUCTION OF N-CARBAMOYL-TERT-LEUCINE

The present invention relates to a process for producing an N-carbamoyl-tert-leucine, characterized in mixing tert-leucine with an isocyanic acid compound while a pH of the mixture is kept at not less than 8.0 and not more than 13.5, wherein an amount of the isocyanic acid compound is not less than 0.9 times by mole and not more than 1.1 times by mole relative to an amount of the tert-leucine. According to the present invention, it becomes possible to easily produce an N-carbamoyl-tert-leucine with high efficiency, while the generation of by-products such as a dipeptide-like compound and a urea compound is prevented.

HEPATITIS C VIRUS INHIBITORS

Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.